PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-116.92%
Negative EBIT growth while TRVN is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-185.87%
Negative operating income growth while TRVN is at 0.00%. Joel Greenblatt would press for urgent turnaround measures.
-92.79%
Negative net income growth while TRVN stands at 0.00%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-3998.91%
Negative EPS growth while TRVN is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-3998.91%
Negative diluted EPS growth while TRVN is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-95.29%
Share reduction while TRVN is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-95.29%
Reduced diluted shares while TRVN is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
75.47%
OCF growth of 75.47% while TRVN is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
66.24%
FCF growth of 66.24% while TRVN is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-141.36%
Negative 10Y OCF/share CAGR while TRVN stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-420.27%
Negative 5Y OCF/share CAGR while TRVN is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-362.87%
Negative 3Y OCF/share CAGR while TRVN stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-427041.90%
Negative 10Y net income/share CAGR while TRVN is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-659606.65%
Negative 5Y net income/share CAGR while TRVN is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-1088784.48%
Negative 3Y CAGR while TRVN is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
-4964.64%
Negative 5Y equity/share growth while TRVN is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-1566.95%
Negative 3Y equity/share growth while TRVN is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1993307.75%
Asset growth of 1993307.75% while TRVN is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
57821.37%
BV/share growth of 57821.37% while TRVN is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
2.24%
Debt growth of 2.24% while TRVN is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
178.96%
R&D growth of 178.96% while TRVN is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
203.49%
SG&A growth of 203.49% while TRVN is zero. Bruce Berkowitz sees more spend on admin or marketing, expecting stronger top-line in return.